On September 3, 2019 Selvita (WSE: SLV) reported that Pawel Przewiezlikowski, Chief Executive Officer, will present at the following conferences in New York (Press release, Selvita, SEP 3, 2019, View Source [SID1234539230]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: H.C. Wainwright 21st Annual Global Investment Conference, Sept. 8-10, 2019
Location: Lotte New York Palace Hotel
Date/Time: Monday, Sept. 9, at 5:30 p.m. EDT
Webcast: A live and archived webcast of this presentation will also be made available at View Source

Event: Rambam Foundation Life Sciences Symposium, Sept. 10, 2019
Location: The YJP Mansion
Date/Time: Tuesday, Sept. 10, at 9:15 a.m. EDT

On September 4, 2019 Castle Biosciences, Inc. (Nasdaq: CSTL) reported that its presentation at the Baird 2019 Global Healthcare Conference in New York City is now scheduled for 3:45 p.m. Eastern time on Wednesday, September 4, 2019 (Press release, Castle Biosciences, SEP 3, 2019, View Source [SID1234539246]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the company’s presentation will be available by visiting Castle Biosciences’ website at View Source A replay of the webcast will be available for two weeks following the conclusion of the live broadcast.

On September 3, 2019 IntelGenx Technologies Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, reported that its CEO, Dr. Horst G. Zerbe, is scheduled to present at the H.C. Wainwright 21st Annual Global Investment Conference on Monday, September 9, 2019 at 1:45 p.m. ET at the Lotte New York Palace Hotel (Press release, IntelGenx, SEP 3, 2019, View Source [SID1234539197]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Zerbe will provide an overview of IntelGenx’s business during the presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

The presentation will be webcast live and archived for 90 days on the Company’s website, at www.intelgenx.com, under "Presentations" in the Investors section.

On September 3, 2019 Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections, reported that senior management will present a corporate overview at the H. C. Wainwright and Company 21st Annual Global Investment Conference on Monday, September 9, 2019 at 2:35 p.m. ET at the Lotte New York Palace Hotel in New York City (Press release, Tetraphase, SEP 3, 2019, View Source [SID1234539214]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the H.C. Wainwright Global Investment Conference presentation will be available on the Company’s website at View Source The archived presentation will be available for 30 days.

On September 3, 2019 Macrophage Pharma Limited (‘MPL’), a company focused on the discovery and development of next-generation immunomodulatory small molecules inducing transcriptional reprofiling of macrophages to combat cancer and other diseases, reported that it has appointed Dr Soren Bregenholt as Chief Executive Officer (Press release, Macrophage Pharma, SEP 3, 2019, View Source [SID1234539231]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Commenting on the appointment, Dr Michael Moore, Chairman of Macrophage Pharma, said: "The Board is delighted to have attracted Søren to Macrophage Pharma. Soren’s outstanding track record from executive positions in both biotech and pharma, as well as his extensive expertise and insight in immunology, will be invaluable as we further develop and commercialise our proprietary Esterase Sensitive Motif (ESM) platform and evolve Macrophage Pharma into a leading biotech company."

Dr Søren Bregenholt, CEO of Macrophage Pharma, said: "I am excited to join Macrophage Pharma as CEO. The Company’s unique and proprietary ESM technology platform is a compelling strategy for inducing transcriptional reprofiling of monocytes and macrophages and represents a differentiated approach to modulation of a centrally important regulator of the immune response across a variety of human diseases. I look forward to working with management and Board to unlock the full therapeutic and commercial potential of the technology in both cancer and non-cancer fields."

Søren Bregenholt PhD is a Danish national with an extensive operational and strategic track record from the biotech and pharmaceutical industries. He previously held senior executive roles including COO and CBO at Danish biotech companies Symphogen and IO Biotech, respectively. As part of the global R&D Management at Novo Nordisk, Søren was responsible for the global R&D Strategy and External Innovation efforts. Currently, Søren serves as Chairman of the Board at the Danish-Swedish life science organization Medicon Valley Alliance. His academic career, at the University of Copenhagen and Institute Pasteur, Paris, has focussed on immunoregulation and immunopathology in cancer and other diseases.